| Literature DB >> 35910976 |
Hartmuth Nowak1, Alexander Wolf1, Tim Rahmel1, Guenther Oprea1, Lisa Grause1, Manuela Moeller2, Katharina Gyarmati3, Corinna Mittler3, Alexandra Zagler4, Katrin Lutz5, Johannes Loeser3, Thomas Saller4, Michael Tryba2,6, Michael Adamzik1, Ernil Hansen5, Nina Zech5.
Abstract
Postoperative nausea and vomiting (PONV) are one of the most adverse events after general anesthesia, a distressing experience, and pose a risk to the patient. Despite advances in drug prophylaxis and PONV treatment, the incidence remains high and additional non-pharmacological treatments are needed. In this post hoc analysis of a recently published double-blind multicenter randomized controlled trial on the efficacy of intraoperative therapeutic suggestions on postoperative opioid dosage, we analyzed the effects of intraoperative therapeutic suggestions on PONV. We focus on patients with a high risk of PONV (Apfel risk score of 3-4) and distinguished early (first two postoperative hours) and delayed PONV (2-24 h). A total of 385 patients with a moderate or high risk for PONV were included. The incidence of early and delayed PONV was reduced (22.7-18.3 and 29.9-24.1%, respectively), without statistical significance, whereas in high-risk patients (n = 180) their incidence was nearly halved, 17.2 vs. 31.2% (p = 0.030) and 20.7 vs. 34.4% (p = 0.040), corresponding to a number needed to treat of 7 to avoid PONV. In addition, there was a significant reduction in PONV severity. In a multivariate logistic regression model, assignment to the control group (OR 2.2; 95% CI: 1.1-4.8) was identified as an independent predictor of the occurrence of early PONV. Our results indicate that intraoperative therapeutic suggestions can significantly reduce the incidence of PONV in high-risk patients. This encourages the expansion of therapeutic suggestions under general anesthesia, which are inexpensive and virtually free of side effects. Clinical Trial Registration: German Clinical Trials Register, https://drks.de, registration number: DRKS00013800.Entities:
Keywords: general anesthesia; hypnotherapy; patient communication; postoperative nausea and vomiting; therapeutic suggestions
Year: 2022 PMID: 35910976 PMCID: PMC9337244 DOI: 10.3389/fpsyg.2022.898326
Source DB: PubMed Journal: Front Psychol ISSN: 1664-1078
FIGURE 1Example text of the therapeutic suggestions used in this study.
FIGURE 2CONSORT flow chart of patient recruitment. No postoperative data were collected for dropouts, and they were excluded from analysis before unblinding of the study. ICU, intensive care unit.
Baseline characteristics for all patients and subgroup of patients at high risk for postoperative nausea and vomiting, defined by pre-operative Apfel-score of 3 or 4.
| All patients ( | Patients at high risk for PONV | |||||
|
|
| |||||
| Intervention group ( | Control group ( |
| Intervention group ( | Control group ( |
| |
| Age (years), median (IQR) | 52 (43–62) | 54 (46–62) | 0.241 | 52 (43–62) | 53 (46–61) | 0.708 |
| Female sex, | 115 (60.2) | 110 (56.7) | 0.484 | 73 (83.9) | 71 (76.3) | 0.205 |
|
| ||||||
| Apfel score | 2 (2–3) | 2 (2–3) | 0.688 | 3 (3–3) | 3 (3–3) | 0.683 |
| HGSHS-5 | 1 (0–3) | 1 (0–3) | 0.798 | 2 (0–4) | 1 (0–3) | 0.483 |
| STAI-S | 41 (33–51) | 40 (33–50) | 0.478 | 43 (33–52) | 44 (34–53) | 0.937 |
| NRS | 0 (0–1) | 0 (0–2) | 0.308 | 0 (0–0) | 0 (0–0) | 0.396 |
|
| ||||||
| Intra-abdominal | 61 (31.9) | 77 (39.7) | 0.489 | 20 (23.0) | 32 (34.4) | 0.040 |
| Thyroid gland | 36 (18.8) | 30 (15.5) | 24 (27.6) | 16 (17.2) | ||
| Gynecological | 24 (12.6) | 15 (17.7) | 21 (24.1) | 11 (11.8) | ||
| Urogenital | 21 (11.0) | 26 (13.4) | 5 (5.7) | 12 (12.9) | ||
| Other | 49 (25.7) | 46 (13.7) | 17 (19.6) | 22 (23.7) | ||
| Duration of surgery (min), median (IQR) | 95 (69–140) | 106 (74–141) | 0.144 | 91 (68–128) | 113 (74–135) | 0.113 |
|
| ||||||
| Fentanyl (mg) | 0.5 (0.4–0.5) | 0.5 (0.5–0.6) | 0.148 | 0.5 (0.4–0.5) | 0.5 (0.4–0.6) | 0.210 |
| Sufentanil (μg) | 50 (40–64) | 50 (40–70) | 0.232 | 50 (39–60) | 50 (40–62) | 0.494 |
| PONV prophylaxis | 94 (49.2) | 99 (51.0) | 0.722 | 55 (63.2) | 61 (65.6) | 0.740 |
Outcome variables for all patients and subgroup of patients at high risk for postoperative nausea and vomiting, defined by a pre-operative Apfel-score of 3 or 4.
| All patients ( | Patients at high risk for PONV | |||||||
|
|
| |||||||
| Intervention group ( | Control group ( |
| NNT | Intervention group ( | Control group ( |
| NNT | |
|
| ||||||||
| Early (within first 2 h) | 35 (18.3) | 44 (22.7) | 0.290 | 23.0 | 15 (17.2) | 29 (31.2) | 0.030 | 7.1 |
| Delayed (2–24 h) | 46 (24.1) | 58 (29.9) | 0.199 | 17.2 | 18 (20.7) | 32 (34.4) | 0.040 | 7.3 |
| Within 24 h | 59 (30.9) | 71 (36.6) | 0.236 | 17.5 | 28 (32.2) | 42 (45.2) | 0.074 | 7.7 |
|
| ||||||||
| Within first 2 h | 0.20 ± 0.52 | 0.26 ± 0.66 | 0.289 | – | 0.16 ± 0.43 | 0.33 ± 0.78 | 0.039 | – |
| Within 24 h | 0.42 ± 0.88 | 0.55 ± 1.09 | 0.173 | – | 0.36 ± 0.88 | 0.74 ± 1.33 | 0.017 | – |
|
| ||||||||
| Within first 2 h | 33 (17.3) | 42 (21.6) | 0.279 | 22.9 | 18 (20.7) | 29 (31.2) | 0.109 | 9.5 |
| Within 24 h | 51 (26.7) | 55 (28.4) | 0.717 | 60.6 | 27 (31.0) | 37 (39.8) | 0.220 | 11.4 |
|
| ||||||||
| Within first 2 h | 0.25 ± 0.66 | 0.30 ± 0.66 | 0.487 | – | 0.30 ± 0.66 | 0.49 ± 0.83 | 0.081 | – |
| Within 24 h | 0.42 ± 0.84 | 0.47 ± 0.90 | 0.524 | – | 0.47 ± 0.85 | 0.75 ± 1.11 | 0.073 | – |
| Within first 2 h, in patients with use of antiemetics | 1.45 ± 0.89 | 1.37 ± 0.73 | 0.695 | – | 1.48 ± 0.61 | 1.56 ± 0.74 | 0.703 | – |
| Within 24 h, in patients with use of antiemetics | 1.54 ± 0.93 | 1.66 ± 0.95 | 0.550 | – | 1.53 ± 0.86 | 1.87 ± 0.99 | 0.142 | – |
Hours refer to timepoint after admission to recovery room. Means, standard deviations, and 95% CIs of non-normally distributed data were calculated by bootstrapping procedure.
FIGURE 3Absolute risk differences of PONV incidence and postoperative use of antiemetics for all patients and subgroup of patients with a high risk for PONV (defined by an Apfel score of 3 or 4).
Correlation between PONV severity and dose of antiemetics.
| Intervention group | Control group | |||||
|
|
| |||||
| Rho | 95% CI |
| Rho | 95% CI |
| |
|
| ||||||
| Intraoperative + first 2 h | 0.295 | 0.090–0.476 | 0.006 | 0.469 | 0.294–0.614 | <0.001 |
| Intraoperative + first 24 h | 0.317 | 0.114–0.494 | 0.003 | 0.415 | 0.231–0.570 | <0.001 |
|
| ||||||
| Intraoperative + first 2 h | 0.325 | −0.055 to 0.623 | 0.092 | 0.530 | 0.269–0.718 | <0.001 |
| Intraoperative + first 24 h | 0.050 | −0.329 to 0.415 | 0.801 | 0.401 | 0.111–0.629 | 0.008 |
PONV severity according to Wengritzky score, antiemetics standardized to antiemetic milligram equivalents (AMEs).
Logistic regression model for single and multiple predictors of postoperative nausea and vomiting in patients with high risk (Apfel score 3–4) (n = 180).
| Univariable models | Multivariable models | ||||||||
|
|
| ||||||||
| Unrestricted | Restricted | ||||||||
|
|
| ||||||||
| OR | 95% CI |
| OR | 95% CI |
| OR | 95% CI |
| |
|
| |||||||||
| No therapeutic suggestions | 2.18 | 1.08–4.51 | 0.032 | 2.23 | 1.05–4.92 | 0.041 | 2.26 | 1.09–4.88 | 0.032 |
| PONV risk score | 2.68 | 1.23–5.80 | 0.012 | 3.31 | 1.40–7.92 | 0.007 | 3.08 | 1.36–7.02 | 0.007 |
| PONV prophylaxis | 1.22 | 0.84–1.80 | 0.297 | 1.13 | 0.70–1.81 | 0.618 | – | – | – |
| Intraoperative fentanyl | 1.15 | 0.35–3.53 | 0.812 | 1.78 | 0.16–19.25 | 0.632 | – | – | – |
| Intraoperative sufentanil | 1.00 | 0.99–1.02 | 0.542 | 1.00 | 0.98–1.03 | 0.771 | – | – | – |
| Type of surgery | |||||||||
| Intra-abdominal | 2.08 | 1.01–4.24 | 0.045 | 3.00 | 1.00–10.05 | 0.059 | 2.66 | 1.17–6.20 | 0.021 |
| Thyroid gland | 1.23 | 0.54–2.68 | 0.611 | 2.06 | 0.60–7.60 | 0.259 | 2.05 | 0.80–5.22 | 0.131 |
| Gynecological | 0.52 | 0.17–1.34 | 0.207 | 0.91 | 0.19–4.05 | 0.897 | – | – | – |
| Urogenital | 0.95 | 0.26–2.85 | 0.927 | 1.81 | 0.36–8.45 | 0.454 | – | – | – |
| Duration of surgery | 1.00 | 1.00–1.01 | 0.337 | 1.00 | 0.99–1.01 | 0.874 | – | – | – |
| Opioid dosage | 1.03 | 0.94–1.12 | 0.493 | 0.97 | 0.88–1.07 | 0.600 | – | – | – |
|
| |||||||||
| No therapeutic suggestions | 2.01 | 1.04–4.00 | 0.042 | 1.78 | 0.84–3.87 | 0.138 | 1.74 | 0.83–3.73 | 0.150 |
| PONV risk score | 2.10 | 0.97–4.48 | 0.055 | 2.59 | 1.08–6.27 | 0.032 | 2.43 | 1.04–5.68 | 0.040 |
| PONV prophylaxis | 1.31 | 0.91–1.89 | 0.151 | 1.02 | 0.61–1.67 | 0.928 | – | – | – |
| Intraoperative fentanyl | 0.44 | 0.13–1.37 | 0.170 | 2.10 | 0.15–24.09 | 0.560 | – | – | – |
| Intraoperative sufentanil | 1.01 | 1.00–1.02 | 0.031 | 1.01 | 0.99–1.04 | 0.372 | – | – | – |
| Type of surgery | |||||||||
| Intra-abdominal | 1.59 | 0.78–3.18 | 0.194 | 1.43 | 0.48–4.48 | 0.525 | – | – | – |
| Thyroid gland | 2.08 | 0.98–4.35 | 0.053 | 2.63 | 0.83–8.93 | 0.109 | 1.85 | 0.80–4.25 | 0.147 |
| Gynecological | 0.22 | 0.05–0.67 | 0.017 | 0.49 | 0.09–2.29 | 0.384 | 0.31 | 0.07–1.02 | 0.081 |
| Urogenital | 1.09 | 0.33–3.13 | 0.874 | 1.62 | 0.34–7.14 | 0.530 | – | – | – |
| Duration of surgery | 1.00 | 0.99–1.01 | 0.913 | 0.99 | 0.98–1.00 | 0.127 | – | – | – |
| Opioid dosage within 24 h | 1.10 | 1.05–1.16 | <0.001 | 1.08 | 1.02–1.15 | 0.009 | 1.08 | 1.03–1.14 | 0.004 |
Hours refer to timepoint after admission to recovery room. Restricted models were built by stepwise backward elimination.